| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 25, 2012Study Results Slated for Presentation in Late-Breaking Clinical Trials Session at Endocrinology Meeting Include Low Event Rates Through Two Years of Follow-Up
MINNEAPOLIS--(BUSINESS WIRE)--May. 25, 2012-- According to study results to be featured in Sunday’s late-breaking clinical trials session at the American Association of Clinical Endocrinologists...
-
May 22, 2012Revenue of $4.3 Billion Grew 4% on a Constant Currency Basis; 3% as Reported
MINNEAPOLIS--(BUSINESS WIRE)--May. 22, 2012-- Medtronic, Inc. (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year ended April 27, 2012. The company reported...
-
May 17, 2012Rigorous Trial Design and Monitoring Provides New Insight to Outcomes for Men and Women with Aortic Stenosis
PARIS--(BUSINESS WIRE)--May. 17, 2012-- Medtronic, Inc. (NYSE: MDT) today announced new results from the Medtronic CoreValve ADVANCE Study, which found that women and men benefitted similarly from...
-
May 16, 2012New Randomized Controlled Trial Results Presented At EuroPCR Demonstrate Clinical Advantages Favoring Drug-Eluting Balloons Over Uncoated Balloons and Stents
PARIS--(BUSINESS WIRE)--May. 16, 2012-- Physicians presented today at EuroPCR 2012 the results of two multicenter, randomized controlled trials, the BELLO and PACIFIER studies, each one showing...
-
May 16, 2012Randomized Controlled Trial Results Presented At EuroPCR Demonstrate Advantages Over Uncoated Angioplasty Balloons and Drug-Eluting Stents
PARIS--(BUSINESS WIRE)--May. 16, 2012-- Please replace the release with the following corrected version due to multiple revisions. The corrected release reads: MEDTRONIC IN.PACT DRUG-ELUTING...
-
May 15, 2012
MINNEAPOLIS--(BUSINESS WIRE)--May. 15, 2012-- Medtronic (NYSE: MDT) will host an institutional investor and analyst meeting on Friday, June 1, 2012, in New York City from 9:00 a.m. to...
-
May 10, 2012
MINNEAPOLIS--(BUSINESS WIRE)--May. 10, 2012-- Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the fourth quarter and fiscal year 2012 on Tuesday, May 22, 2012. A...
-
Apr 27, 2012Six Month Pooled Outcomes From Randomized and Crossover Patients Following Renal Denervation Presented at the 22nd Annual Scientific Meeting of the European Society of Hypertension Confirm Previous Symplicity Clinical Trial Findings
MINNEAPOLIS & LONDON, Apr 27, 2012 (BUSINESS WIRE) --Medtronic, Inc., (NYSE: MDT), announced today six month pooled outcomes from randomized and crossover patients in the Symplicity HTN-2 clinical...
-
Mar 26, 2012ACC.12 Late-breaker Shows Promise of Pacemakers through Diminishing Fainting Recurrences in Patients Diagnosed with Syncope
MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--Mar. 26, 2012-- Medtronic, Inc. (NYSE: MDT) today announced the results of a double-blind, randomized study, ISSUE-3, which found that patients who suffered...
-
Mar 25, 2012Data from Two Clinical Trials Presented at the 61st Annual Scientific Session of the American College of Cardiology Show Consistent Effectiveness and Safety Up to Three Years
MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--Mar. 25, 2012-- Medtronic, Inc. (NYSE:MDT), announced that the Symplicity™ renal denervation system provides safe, significant and sustained blood...